UK

EU flag
#Cancer Research UK #Drug research #Funding #Horizon Europe #Investment #UK

What’s on the horizon for UK drug discovery?

Editor Reece Armstrong provides an introduction to the Fall 2023 issue of Drug Discovery World. Find out more about the issue and how to read it. That this issue should feature a market report on the state of the United Kingdom’s drug discovery… Read More

#Exclusive Content #Opinion

#ABPI #Association of the British Pharmaceutical Industry #Pharmaceutical industry #UK #UK government

Industry rejects ‘damaging’ changes to UK medicines scheme

Over twenty pharma companies have rejected the UK government’s proposed changes to the statutory scheme for branded medicines, the latest move in an ongoing disagreement between the government and industry. According to the Association of the British Pharmaceutical industry (ABPI), the “radical plans” are “unworkable”. And… Read More

#News

PET scanner
#Imaging #Innovate UK #Medical Research Council #Medicines Discovery Catapult (MDC) #PET technology #UK

Total-body PET scanners will enhance UK drug discovery

A national total-body positron emission tomography (PET) imaging platform for drug discovery is launching in the UK next year. It is hoped that the National PET Imaging Platform (NPIP) will transform medical research and industrialise cutting-edge technology, enhancing the quality and speed of drug discovery. Read More

#News

Stamp of approval
#Chiesi #National Institute for Health and Care Excellence (NICE) #Rare disease #UK

NICE recommends enzyme therapy for Fabry disease

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Elfabrio (pegunigalsidase alfa) as an option for treating Fabry disease (or alpha-galactosidase deficiency). The drug is recommended for use on the NHS under the terms of a confidential commercial agreement. Pegunigalsidase alfa… Read More

#News #Regulatory

Breast cancer
#Arvinas #Breast cancer #Cancer research #Oncology #Pfizer #UK

ER degrader for breast cancer receives UK Innovation Passport

Arvinas and Pfizer UK have been awarded a UK Innovation Passport for vepdegestrant (ARV-471), an investigational PROTAC ER (estrogen receptor) degrader. It is intended for the treatment of patients with oestrogen receptor (ER)+/ human epidermal growth factor receptor (HER)2- locally-advanced breast cancer or metastatic breast cancer. Read More

#News #Regulatory

#ABPI #Big pharma #Biopharma #Covid-19 #Ipsos #UK

Pharma maintains high level of trust from UK public and doctors

The pharmaceutical industry continues to maintain strong levels of public trust and favourability in the UK, according to data from the Association of the British Pharmaceutical Industry (ABPI). Opinions showed consistent recognition of the sector’s support for the NHS, with 67% of respondents saying the industry… Read More

#News

Great British Pounds, Investment
#ABPI #BioIndustry Association #Biologics / Biotechnology #Clarivate #Financing #Investment #UK

UK biotech financing up 29% on last quarter

The second quarter of 2023 has seen steady growth in financing activity for the UK’s life sciences sector, according to new data released by the BioIndustry Association (BIA) and Clarivate. The positive news comes soon after industry figures welcomed recent announcements to unlock new sources of… Read More

#Business & Investment #News

Vaccine research
#Covid-19 #Disease X #Immunology / Virology & Vaccines #Pandemic prevention #Pandemic response #UK

UK vaccine centre offers opportunity for pandemic preparedness

A new Vaccine Development and Evaluation Centre (VDEC) has been unveiled in the UK, with the aim of building on the UK’s pandemic legacy and helping develop life-saving new vaccines that will fight ‘Disease X‘, a term used because what might trigger the next pandemic is unknown. Read More

#News #Trending News

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK budget

Two part commentary on Brexit and drug discovery

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory… Read More

#News

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK budget

Part 1: What impact has Brexit had on UK drug discovery?

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory… Read More

#Exclusive Content #Regulatory

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK bidget

Part 2: What impact has Brexit had on UK drug discovery?

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory… Read More

#Exclusive Content #Regulatory

New Domainex facility
#Contract Research Organisations (CROs) #Domainex #UK #University College London

Domainex expands research operations with new facility

Research services provider Domainex has secured a new, fully fitted, three-storey building in Unity Campus in Cambridgeshire, UK. Domainex first moved to Unity Campus in January 2022, taking 7,000 sq ft of laboratory space at Iconix 2 to provide a dedicated facility for its biology department… Read More

#News

#Healthcare #Life sciences #NHS #Revvity #UK

Revvity opens Scientific Centre of Excellence for genomics

Global health science solutions company Revvity, PerkinElmer’s Life Science and Diagnostics business’ new name and branding, has announced the establishment of a Scientific Centre of Excellence in Cambridge, UK.   Focused on driving genomic insights to accelerate therapeutic discovery, Revvity’s Scientific Centre of… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

DDW Highlights podcast: New episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Despite the bad news for the UK life sciences industry this week that international investment dropped… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

This week in drug discovery (3-7 July)  

News round-up for 10-14 July by DDW Digital Content Editor Diana Spencer. Despite the bad news for the UK life sciences industry this week that international investment dropped nearly 50% in 2022, both private and public funding activity has continued apace in the wider drug discovery… Read More

#News